Regeneron Pharmaceuticals, Inc. (REGN) Tax Rate: 13.88%
Is Regeneron Pharmaceuticals, Inc.’s tax rate high or low?
Regeneron Pharmaceuticals, Inc.'s tax rate of 13.88% is 40% above its 5-year average of 9.89%, near the high end of its 5-year range (5.85%–13.88%).
The tax rate for Regeneron Pharmaceuticals, Inc. (REGN) is 13.88%. It is above its 12-month average by 28.76% (10.78%).
REGN Tax Rate Chart
REGN Average Tax Rate Chart
REGN Current vs Average Tax Rate Chart
REGN Tax Rate Metrics
TAX RATE
13.88%
TAX RATE AVG TTM
10.78%
TAX RATE AVG 3Y
9.53%
TAX RATE AVG 5Y
9.89%
TAX RATE AVG 10Y
18.14%
TAX RATE AVG 15Y
13.42%
TAX RATE AVG 20Y
19.86%
CURRENT VS TTM AVG
+28.76%
CURRENT VS 3Y AVG
+45.65%
CURRENT VS 5Y AVG
+40.37%
CURRENT VS 10Y AVG
-23.50%
CURRENT VS 15Y AVG
+3.44%
CURRENT VS 20Y AVG
-30.11%
Regeneron Pharmaceuticals, Inc. Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Regeneron Pharmaceuticals, Inc. Tax Rate FAQ
- What is the tax rate for Regeneron Pharmaceuticals, Inc. (REGN)?
- The tax rate for REGN stock is 13.88%.
- Is Regeneron Pharmaceuticals, Inc.'s tax rate high or low?
- Regeneron Pharmaceuticals, Inc.'s tax rate of 13.88% is 40% above its 5-year average of 9.89%, near the high end of its 5-year range (5.85%–13.88%).
- What is the TTM average tax rate for Regeneron Pharmaceuticals, Inc. (REGN)?
- The TTM average tax rate for REGN stock is 10.78%.
- What is the 3Y average tax rate for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 3Y average tax rate for REGN stock is 9.53%.
- What is the 5Y average tax rate for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 5Y average tax rate for REGN stock is 9.89%.
- What is the 10Y average tax rate for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 10Y average tax rate for REGN stock is 18.14%.
- What is the 15Y average tax rate for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 15Y average tax rate for REGN stock is 13.42%.
- What is the 20Y average tax rate for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 20Y average tax rate for REGN stock is 19.86%.
Regeneron Pharmaceuticals, Inc. Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | 13.88% |
| 2024-12-31 | 7.68% |
| 2023-12-31 | 5.85% |
| 2022-12-31 | 10.71% |
| 2021-12-31 | 13.41% |
| 2020-12-31 | 7.80% |
| 2019-12-31 | 12.90% |
| 2018-12-31 | 4.27% |
| 2017-12-31 | 42.34% |
| 2016-12-31 | 32.66% |
| 2015-12-31 | 48.08% |
| 2014-12-31 | 55.13% |
| 2013-12-31 | 40.51% |
| 2012-12-31 | -81.04% |
| 2011-12-31 | 0.51% |
| 2010-12-31 | 0.00% |
| 2009-12-31 | 5.73% |
| 2008-12-31 | -2.93% |
| 2007-12-31 | 31.80% |
| 2006-12-31 | 24.00% |
| 2005-12-31 | 143.74% |
| 2004-12-31 | -156.44% |
| 2003-12-31 | -3.15% |
| 2002-12-31 | 6.23% |
| 2001-12-31 | 29.46% |
| 2000-12-31 | -8.42% |
| 1999-12-31 | 7.46% |
| 1998-12-31 | 102.44% |
| 1997-12-31 | -100.00% |
| 1996-12-31 | -169.94% |
Related Metrics
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Schleifer